BioCryst Pharmaceuticals, Inc. (BMV:BCRX)

Market Cap	42.49B
Revenue (ttm)	10.29B
Net Income (ttm)	-1.09B
Shares Out	n/a
EPS (ttm)	-5.30
PE Ratio	n/a
Forward PE	32.06
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45
Average Volume	394
Open	210.00
Previous Close	138.00
Day's Range	210.00 - 215.00
52-Week Range	98.86 - 170.00
Beta	n/a
RSI	51.85
Earnings Date	May 5, 2025

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1986
• Employees: 580
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BCRX

Financial Performance

In 2024, BioCryst Pharmaceuticals's revenue was $450.71 million, an increase of 36.00% compared to the previous year's $331.41 million. Losses were -$88.88 million, -60.77% less than in 2023.

Financial numbers in USD